Live
Suven Life Sciences has received product patent each from African Regional Intellectual Property Organisation (Aripo) and South Korea, corresponding to new chemical entities (NCEs), for treating disorders related with neurodegenerative diseases.
Venkat Jasti, Suven Life CEO stated, “We are pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
Both the patents are valid till 2033 and 2034, respectively. Further, as per the company, the patents are being developed as therapeutic agents and are useful for treating cognitive impairment related to neurodegenrative disorders.
